CRISPR gene editing technology is revolutionizing healthcare as we know it.
The technology, which earned two of its discoverers a Nobel Prize in 2020, can target and edit genes more easily and more precisely than its predecessors.
Yet as promising as CRISPR has been over the past several years, it’s mostly been developed in the lab.
Thankfully, that is now changing as a growing number of clinical trials are beginning to test gene therapies in humans.
Early CRISPR trials have focused on hereditary blindness and diseases of the blood, including cancer and sickle cell anemia.
The problem is that although cutting-edge, these therapies can be costly and intense. For example, in one trial for sickle cell anemia, doctors remove cells from the body, edit them in a dish, and then infuse them back into the patient.
Such a complicated approach won’t work as readily for other diseases.
What we need is a general delivery method for CRISPR, so that it can be used like any other medication.
And a recent clinical trial run by researchers at University College London (UCL) has made a key, promising step in that direction. Discussing the latest developments in biotech—using biology astechnology—is a key focus of my year-round coaching program Abundance360.
Continue reading… “CAN CRISPR GENE THERAPY BE A SINGLE INJECTION?”